Author: [email protected]

November 10, 2022 at 9:00 AM EST

November 3, 2022 at 6:00 AM EDT

BOULDER, Colo.–(BUSINESS WIRE)–Oct. 20, 2022– Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus on lung disease, today announced that it will release financial results for the third quarter ended September 30, 2022 before the open of trading on Thursday, November 3. Biodesix’s management will host a conference call and webcast to discuss its financial results…

Expands Coverage to Veterans Health Administration and Military Health System Medical Centers for Its Entire Lung Diagnostic Portfolio

Biodesix to Present Data at the CHEST 2022 Annual Meeting Demonstrating High Sensitivity of the Nodify XL2® Blood-Based Lung Nodule Test in Various Patient Populations, Including Individuals Participating in Lung Cancer Screening Programs

Third quarter 2022 core lung diagnostic testing revenues growth up 96% to 103% compared to third quarter 2021 

BOULDER, Colo.–(BUSINESS WIRE)–Sep. 6, 2022– Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will participate in two upcoming investor conferences:

Aug 10, 2022 at 3:00 PM EDT

BOULDER, Colo.–(BUSINESS WIRE)– Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced it has been recognized in the Healthcare Technology Report’s Top 100 Healthcare Technology Companies of 2022. The company develops and commercializes blood-based diagnostic tests designed to address important unmet needs in healthcare, by combining…

August 4, 2022 at 6:00 AM EDT